NEW YORK – Machine learning diagnostic firm Prevencio announced Tuesday it is collaborating with Seattle Children's Research Institute to develop a blood test for Kawasaki disease.
The institute will provide Prevencio with blood samples and the firm will use its HART AI platform to develop a blood test for the disease. Under the agreement, Prevencio will retain exclusive global rights to the test. The firm will use its laboratory partner Myriad RBM to measure proteins in the blood samples.
Additional terms of the deal were not disclosed.